On September 18, 2023, William B. Stilley, a member of Adial Pharmaceuticals, Inc. Board of Directors (the ?Board?), notified the Company of his decision to resign, effective as such date, from his position as a member of the Board and any other executive positions with the Company and its subsidiaries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.55 USD | +9.93% | +3.33% | -16.67% |
22/04 | Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder | MT |
12/04 | Top Premarket Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.67% | 5.72M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- ADIL Stock
- News Adial Pharmaceuticals, Inc.
- Adial Pharmaceuticals, Inc. Announces Board Changes